⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AGEN News
Agenus Inc.
Agendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast Cancer
businesswire.com
AGEN
アジーナス、BOT+BALアクセスプログラムの独占的グローバルパートナーにBAP Pharmaを指名
businesswire.com
AGEN
Agenus designa a BAP Pharma como socio global exclusivo para BOT+BAL
businesswire.com
AGEN
Agenus ernennt BAP Pharma zum exklusiven globalen Partner für die BOT+BAL-Zugangsprogramme
businesswire.com
AGEN
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
businesswire.com
AGEN
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
businesswire.com
AGEN
アジーナス、MSSまたはpMMRの転移性大腸がんを対象としたBOT+BAL免疫療法併用のグローバル第3相BATTMAN試験で初の患者登録を発表
businesswire.com
AGEN
Agenus annonce le recrutement du premier patient dans l’essai mondial de phase III BATTMAN portant sur l’association immunothérapeutique BOT+BAL dans le cadre du cancer colorectal métastatique MSS ou pMMR
businesswire.com
AGEN
Agenus annuncia il primo paziente registrato in BATTMAN, il trial clinico globale di fase 3 sulla combinazione di immunoterapia BOT+BAL nel cancro del colorettale in fase avanzata MSS o pMMR
businesswire.com
AGEN
Agenus inicia el ensayo global de fase 3 BATTMAN con la inclusión del primer paciente para la combinación inmunoterapéutica BOT+BAL en cáncer colorrectal metastásico MSS o pMMR
businesswire.com
AGEN